Tag: Aidixi®

Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin

Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints

Disitamab Vedotin Gains Approval in China for its Third Indication

In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung...

During the upcoming European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain, Pfizer is presenting encouraging early results for preliminary efficacy and safety data for disitamab vedotin* in combination with pembrolizumab (Keytruda®; Merck & Co), and results from an additional analysis from the pivotal EV-302 trial supporting the combination of enfortumab vedotin (Padcev®; Astellas/Pfizer) and pembrolizumab (Keytruda®; Merck & Co) as a new standard of care for patients with previously untreated la/mUC.

RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical Products Administration (NMPA; 国家药品监督管理局) of...